Health · Planned · 4 sources combined
14 Rare-Disease Drugs Applied
Selection Fairness Questioned
In short
A pilot program is underway to speed up coverage of rare-disease treatments under national health insurance.
Thirteen pharmaceutical companies applied for about 14 drugs, and the government reviewed them on the 4th.
Patient groups demanded fairness in the selection process and priority for patient treatment.
Key facts
| When | Patient groups released their position on November 2nd, and the government held a selection review committee meeting on the 4th. |
|---|---|
| Who | The Korea Patient Groups Association and the Korea Rare and Intractable Disease Association each issued statements. |
| What | The issue concerns selection of 14 rare-disease treatment drugs applied for by 13 pharmaceutical companies for expedited coverage. |
| How | The patient groups association refused to participate in the review citing fairness concerns, while the rare disease association demanded broader selection. |
What it means for me
Rare-disease patients and their families are directly affected by whether treatment drugs are covered by national health insurance.
